Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

NCT04911959 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Lenvatinib

Interventions

DRUG: Lenvatinib
PROCEDURE: TACE

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University